The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 4, 2008, Pages 748-752

  Shilling, Paul D ^a   Feifel, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal model; Anxiety; Anxiolytic; Fear potentiated; Neurotensin; Startle

Indexed keywords

DRUG VEHICLE; NEUROTENSIN 1 RECEPTOR AGONIST; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; PD 149163; SODIUM CHLORIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FEAR; FOOTSHOCK; MALE; NEUROMODULATION; NOISE; NONHUMAN; PRIORITY JOURNAL; RAT; STARTLE REFLEX; TRANQUILIZING ACTIVITY; WHITE LIGHT;

ACOUSTIC STIMULATION; ANIMALS; ANTI-ANXIETY AGENTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; MALE; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; STARTLE REACTION;

ANIMALIA; RATTUS;

EID: 48749088141     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.05.025     Document Type: Article

References (54)

1. Alexander M.J., and Leeman S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J Comp Neurol 402 (1998) 475-500
2. Azmi N., Norman C., Spicer C.H., and Bennett G.W. Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task. Behav Pharmacol 17 (2006) 357-362
3. Batten T.F., Gamboa-Esteves F.O., and Saha S. Evidence for peptide co-transmission in retrograde- and anterograde-labelled central nucleus of amygdala neurones projecting to NTS. Auton Neurosci 98 (2002) 28-32
4. Beck C.H., and Fibiger H.C. Conditioned fear-induced changes in behavior and in the expression of the immediate early gene cfos: with and without diazapam. J. Neurosci. 15 1 Pt2 (1995) 709-720
5. Berg W.K., and Davis M. Diazepam blocks fear-enhanced startle elicited electrically from the brainstem. Physiol Behav 32 2 (1984) 333-336
6. Boules M., Fredrickson P., and Richelson E. Neurotensin agonists as an alternative to antipsychotics. Expert Opin Investig Drugs 14 (2005) 359-369
7. Boules M., Shaw A., Fredrickson P., and Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21 (2007) 13-23
8. Britton J.C., Phan K.L., Taylor S.F., Fig L.M., and Liberzon I. Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery. Biol Psychiatry 57 (2005) 832-840
9. Burghardt N.S., Sullivan G.M., McEwen B.S., Gorman J.M., and LeDoux J.E. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 55 (2004) 1171-1178
10. Campeau S., Miserendino M.J., and Davis M. Intra-amygdala infusion of the N-methyl-d-aspartate receptor antagonist AP5 blocks acquisition but not expression of fear-potentiated startle to an auditory conditioned stimulus. Behav Neurosci 106 (1992) 569-574
11. Cannistraro P.A., Wright C.I., Wedig M.M., et al. Amygdala responses to human faces in obsessive-compulsive disorder. Biol Psychiatry 56 (2004) 916-920
12. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., and Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res 856 (2000) 48-54
13. Davis M., and Shi C. The amygdala. Curr Biol 10 (2000) R131
14. Davis M., Falls W.A., Campeau S., and Kim M. Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58 (1993) 175-198
15. Emson P.C., Goedert M., Horsfield P., Rioux F., and St Pierre S. The regional distribution and chromatographic characterisation of neurotensin-like immunoreactivity in the rat central nervous system. J Neurochem 38 (1982) 992-999
16. Feifel D., Minor K.L., Dulawa S., and Swerdlow N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res 760 (1997) 80-84
17. Feifel D., Reza T.L., Wustrow D.J., and Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 288 (1999) 710-713
18. Feifel D., Melendez G., and Shilling P.D. PD149163, a neurotensin agonist, attenuates prepulse inhibition deficits produced by dizocilpine and DOI. Neuropsychopharmacology 28 (2003) 651-653
19. Feifel D., Melendez G., and Shilling P.D. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology 28 (2003) 651-653
20. Feifel D., Melendez G., and Shilling P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29 (2004) 731-738
21. Feifel D., Melendez G., Priebe K., and Shilling P.D. The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 81 (2007) 278-286
22. Feighner J.P., and Boyer W.F. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. J Clin Psychiatry 53 (1992) 44-47 Suppl
23. Fredrickson P., Boules M., Lin S.C., and Richelson E. Neurobiologic basis of nicotine addiction and psychostimulant abuse: a role for neurotensin?. Psychiatr Clin North Am 28 737-51 (2005) 746
24. Gewirtz J.C., McNish K.A., and Davis M. Is the hippocampus necessary for contextual fear conditioning?. Behav Brain Res 110 (2000) 83-95
25. Goldstein B.J., and Goodnick P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12 (1998) S55-S87
26. Goodnick P.J., and Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-II. Efficacy and quality of life. J Psychopharmacol 12 (1998) S21-S54
27. Kalivas P.W., Nemeroff C.B., and Prange Jr. A.J. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience 11 (1984) 919-930
28. Kanba K.S., Kanba S., Nelson A., Okazaki H., and Richelson E. [3H]neurotensin(8-13) binds in human brain to the same sites as does [3H]neurotensin but with higher affinity. J Neurochem 50 (1988) 131-137
29. Kehne J.H., Casella J.V., and Davis M. Anxiolytic effects of busirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology (Berl) 94(1) (1988) 8-13
30. Lambert P.D., Ely T.D., Gross R.E., and Kilts C.D. Neurotensin induces Fos and Zif268 expression in limbic nuclei of the rat brain. Neuroscience 75 (1996) 1141-1151
31. LeDoux J.E. Emotion circuits in the brain. Annu Rev Neurosci 23 (2000) 155-184
32. Machida R., Tokumura T., Tsuchiya Y., Sasaki A., and Abe K. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats. Biol Pharm Bull 16 (1993) 43-47
33. Mansbach R.S., and Geyer M.A. Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands. Eur J Pharmacol 156(3) (1988) 375-383
34. Mansbach R.S., Geyer M.A., and Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94 (1988) 507-514
35. Milham M.P., Nugent A.C., Drevets W.C., et al. Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry 57 (2005) 961-966
36. Mora P.O., Netto C.F., and Graeff F.G. Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem Behav 58 (1997) 1051-1057
37. Myers K., Goulet M., Rusche J., Boismenu R., and Davis M. Inhibition of fear potentiated startle in rats following peripheral administration of secretin. Psychopharmacology (Berl) 172 (2004) 94-99
38. Nakachi N., Yamada M., Cho T., Coleman N.J., Yamada M., and Richelson E. Expression of mRNA for neurotensin in rat brain cholinergic neurons. Biol Psychiatry 37 (1995) 642
39. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, New York, New York
40. Petrie K.A., Bubser M., Casey C.D., Davis M.D., Roth B.L., and Deutch A.Y. The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology 29 (2004) 1878-1888
41. Richelson E., Fredrickson P.A., and Boules M.M. Neurotensin receptor agonists and antagonists for schizophrenia. Am J Psychiatry 162 (2005) 633-634 author reply 635
42. Rickels K., and Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63 Suppl 14 (2002) 9-16
43. Robledo P., Maldonado R., and Koob G.F. Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Res 622 (1993) 105-112
44. Saiz Ruiz J., Carrasco Perera J.L., and Hernanz A. [Plasma neuropeptides in affective and anxiety disorders]. Arch Neurobiol (Madr) 55 (1992) 1-5
45. Shilling P.D., Richelson E., and Feifel D. NT69L, a neurotensin agonist, produces antipsychotic-like effects on prepulse inhibition of startle. Behav Brain Res 143 (2003) 7-14
46. Shilling P.D., Melendez G., Priebe K., Richelson E., and Feifel D. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist. Psychopharmacology (Berl) 175 (2004) 353-359
47. Shugalev I.P., Ol'shanskii A.S., Lenard L., and Hartmann G. [Effects of neurotensin on active and passive avoidance performance in rats with lesions of serotoninergic neurons]. Zh Vyssh Nerv Deiat Im I P Pavlova 55 (2005) 247-252
48. Skoog K.M., Cain S.T., and Nemeroff C.B. Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine. Neuropharmacology 25 (1986) 777-782
49. Szigethy E., and Beaudet A. Selective association of neurotensin receptors with cholinergic neurons in the rat basal forebrain. Neurosci Lett 83 (1987) 47-52
50. Walker D.L., and Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 71 (2002) 379-392
51. Weisstaub N.V., Zhou M., Lira A., et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313 (2006) 536-540
52. Winslow J.T., Noble P.L., and Davis M. Modulation of fear-potentiated startle and vocalizations in juvenile rhesus monkeys by morphine, diazepam, and buspirone. Biol Psychiatry 61(3) (2007) 389-395
53. Wustrow D.J., Davis M.D., Akunne H.C., et al. Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity. Bioorg Med Chem Lett 5 (1995) 997-1002
54. Yamauchi R., Wada E., Yamada D., Yoshikawa M., and Wada K. Effect of beta-lactotensin on acute stress and fear memory. Peptides 27 (2006) 3176-3182